The value of biosamples in smoking cessation trials: A review of genetic, metabolomic, and epigenetic findings

Nicotine and Tobacco Research

Volumn 20, Issue 4, 2018, Pages 403-413

  Saccone, Nancy L ^a   Baurley, James W ^b   Bergen, Andrew W ^b   David, Sean P ^c   Elliott, Hannah R ^d   Foreman, Marilyn G ^e   Kaprio, Jaakko ^f   Piasecki, Thomas M ^g   Relton, Caroline L ^d   Zawertailo, Laurie ^h   Bierut, Laura J ⁱ   Tyndale, Rachel F ^h   Chen, Li Shiun ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Biorealm   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UNIVERSITY OF MISSOURI   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT; BIOLOGICAL MARKER;

CHRNA5 GENE; CLINICAL RESEARCH; CONTROLLED STUDY; EPIGENETICS; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEALTH HAZARD; HUMAN; METABOLITE; METABOLOMICS; MOTIVATION; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; CLINICAL TRIAL (TOPIC); GENETIC EPIGENESIS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; THERAPY;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; GENOTYPE; HUMANS; METABOLOMICS; PHARMACOGENETICS; PRECISION MEDICINE; SMOKING; SMOKING CESSATION;

EID: 85043571226     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx096     Document Type: Review

References (120)

1. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370(1):60-68.
2. WHO. WHO global report on mortality attributable to tobacco. Geneva: World Health Organization; 2012.
3. Bilano V, Gilmour S, Moffiet T, et al. Global trends and projections for tobacco use, 1990-2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet. Mar 14 2015;385(9972):966-976.
4. Schlam TR, Baker TB. Interventions for tobacco smoking. Annu Rev Clin Psychol. 2013;9:675-702.
5. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204-213.
6. Gelernter J. Genetics of complex traits in psychiatry. Biol Psychiatry. 2015;77(1):36-42.
7. Kendler KS, Chen X, Dick D, et al. Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci. 2012;15(2):181-189.
8. Loukola A, Hällfors J, Korhonen T, Kaprio J. Genetics and smoking. Curr Addict Rep. 2014;1(1):75-82.
9. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 2011;69(4):618-627.
10. Bierut LJ, Johnson EO, Saccone NL. A glimpse into the future -personalized medicine for smoking cessation. Neuropharmacology. 2014;76(Pt B):592-599.
11. Chen LS, Horton A, Bierut L. Pathways to precision medicine in smoking cessation treatments [published online ahead of print May 18, 2016]. Neurosci Lett. 2016. http://dx.doi.org/10.1016/j.neulet.2016.05.033.
12. Mamoun M, Bergen AW, Shieh J, Wiggins A, Brody AL. Biomarkers of response to smoking cessation pharmacotherapies: progress to date. CNS Drugs. 2015;29(5):359-369.
13. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526-538.
14. Chen LS, Hung RJ, Baker T, et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis -a meta-analysis. J Natl Cancer Inst. 2015;107(5).
15. Olfson E, Saccone NL, Johnson EO, et al. Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans. Mol Psychiatry. 2015;21(5):601-607.
16. The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42(5):441-447.
17. Vrieze SI, McGue M, Iacono WG. The interplay of genes and adolescent development in substance use disorders: leveraging findings from GWAS meta-analyses to test developmental hypotheses about nicotine consumption. Hum Genet. 2012;131(6):791-801.
18. Bloom AJ, Hartz SM, Baker TB, et al. Beyond cigarettes per day. A genomewide association study of the biomarker carbon monoxide. Ann Am Thorac Soc. 2014;11(7):1003-1010.
19. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. Nature. 2007;447(7145):655-660.
20. Munafò MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20(9):439-444.
21. Sullivan PF. Spurious genetic associations. Biol Psychiatry. 2007;61(10):1121-1126.
22. Haller G, Druley T, Vallania FL, et al. Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. Hum Mol Genet. 2012;21(3):647-655.
23. Xie P, Kranzler HR, Krauthammer M, et al. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry. 2011;70(6):528-536.
24. Wessel J, McDonald SM, Hinds DA, et al. Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence. Neuropsychopharmacology. 2010;35(12):2392-2402.
25. Yang J, Wang S, Yang Z, et al. The contribution of rare and common variants in 30 genes to risk nicotine dependence. Mol Psychiatry. 2015;20(11):1467-1478.
26. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14(6):379-389.
27. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
28. Keskitalo K, Broms U, Heliövaara M, et al. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet. 2009;18(20):4007-4012.
29. Munafò MR, Timofeeva MN, Morris RW, et al.; EPIC Study Group. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst. 2012;104(10):740-748.
30. Ware JJ, Chen X, Vink J, et al. Genome-wide meta-analysis of cotinine levels in cigarette smokers identifies locus at 4q13.2. Sci Rep. 2016;6:20092.
31. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64-72.
32. Loukola A, Buchwald J, Gupta R, et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet. 2015;11(9):e1005498.
33. Bergen AW, Michel M, Nishita D, et al.; Transdisciplinary Research in Cancer of the Lung Research Team. Drug metabolizing enzyme and transporter gene variation, nicotine metabolism, prospective abstinence, and cigarette consumption. PLoS One. 2015;10(7):e0126113.
34. Baurley JW, Edlund CK, Pardamean CI, et al. Genome-wide association of the laboratory-based nicotine metabolite ratio in three ancestries. Nicotine Tob Res. 2016;18(9):1837-1844.
35. Lerman C, Schnoll RA, Hawk LW Jr, et al.; PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131-138.
36. Patel YM, Park SL, Han Y, et al. Novel association of genetic markers affecting CYP2A6 activity and lung cancer risk. Cancer Res. 2016;76(19):5768-5776.
37. Chen L-S, Zawertailo L, Piasecki TM, et al. Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how [published online ahead of print May 12, 2017]. Nicotine Tob Res. 2018;20(4):414-424.
38. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642.
39. Hancock DB, Reginsson GW, Gaddis NC, et al. Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Transl Psychiatry. 2015;5:e651.
40. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448-453.
41. Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a metaanalysis and comparison with lung cancer and COPD. PLoS Genet. 2010;6(8):e1001053.
42. David SP, Hamidovic A, Chen GK, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry. 2012;2:e119.
43. Liu JZ, Tozzi F, Waterworth DM, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. May 2010;42(5):436-440.
44. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616-622.
45. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633-637.
46. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5(3):e1000421.
47. Cho MH, McDonald ML, Zhou X, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med. 2014;2(3):214-225.
48. Freathy RM, Ring SM, Shields B, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet. 2009;18(15):2922-2927.
49. Chen LS, Baker TB, Piper ME, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry. 2012;169(7):735-742.
50. Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013;23(2):94-103.
51. Kumasaka N, Aoki M, Okada Y, et al. Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. PLoS One. 2012;7(9):e44507.
52. Patel YM, Park SL, Han Y, et al. Novel association of genetic markers affecting CYP2A6 activity and lung cancer risk. Cancer Res. Aug 3 2016.
53. Bloom AJ, Harari O, Martinez M, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum Mol Genet. 2012;21(13):3050-3062.
54. Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010;87(5):553-557.
55. Chen LS, Bloom AJ, Baker TB, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2014;109(1):128-137.
56. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16(1):36-49.
57. Zhu AZ, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction. 2013;108(10):1818-1828.
58. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165(9):1163-1171.
59. Amos CI, Gorlov IP, Dong Q, et al. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst. 2010;102(15):1199-1205.
60. Wang JC, Grucza R, Cruchaga C, et al. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry. 2009;14(5):501-510.
61. Wang JC, Cruchaga C, Saccone NL, et al. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 2009;18(16):3125-3135.
62. Smith RM, Alachkar H, Papp AC, et al. Nicotinic alpha5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. Eur J Hum Genet. 2010;19(1):76-83.
63. Chen LS, Saccone NL, Culverhouse RC, et al. Smoking and genetic risk variation across populations of European, Asian, and African American ancestry-a meta-analysis of chromosome 15q25. Genet Epidemiol. 2012;36(4):340-351.
64. Li MD, Yoon D, Lee JY, et al. Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. PLoS One. 2010;5(8):e12183.
65. Sarginson JE, Killen JD, Lazzeroni LC, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):275-284.
66. Zhu AZ, Zhou Q, Cox LS, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin Pharmacol Ther. 2014;96(2):256-265.
67. Munafo MR, Johnstone EC, Walther D, et al. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res. 2011;13(10):982-988.
68. Chen LS, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278-282.
69. Kaufman JS, Harper S. Deficiency of the odds ratio for common outcomes. Am J Psychiatry. 2012;169(10):1118.
70. Chen LS, Baker TB, Bierut LJ. Response to Kaufman and Harper letter. Am J Psychiatry. 2012;169(10):1118-1119.
71. Leung T, Bergen A, Munafò MR, De Ruyck K, Selby P, De Luca V. Effect of the rs1051730-rs16969968 variant and smoking cessation treatment: a meta-analysis. Pharmacogenomics. 2015;16(7):713-720.
72. Tyndale RF, Zhu AZ, George TP, et al.; PGRN-PNAT Research Group. Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. PLoS One. 2015;10(5):e0128109.
73. Chen LS, Baker TB, Piper ME, et al. Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. Drug Alcohol Depend. 2014;143:36-43.
74. Ware JJ, Aveyard P, Broderick P, Houlston RS, Eisen T, Munafò MR. The association of rs1051730 genotype on adherence to and consumption of prescribed nicotine replacement therapy dose during a smoking cessation attempt. Drug Alcohol Depend. 2015;151:236-240.
75. King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37(3):641-650.
76. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57-71.
77. Tanner JA, Chenoweth MJ, Tyndale RF. Pharmacogenetics of nicotine and associated smoking behaviors. Curr Top Behav Neurosci. 2015;23:37-86.
78. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212-1217.
79. Nakajima M, Yamamoto T, Nunoya K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996;277(2):1010-1015.
80. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340.
81. Bloom AJ, Baker TB, Chen LS, et al. Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Hum Mol Genet. 2014;23(2):555-561.
82. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3' hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19(5):388-398.
83. Chenoweth MJ, Novalen M, Hawk LW Jr, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1773-1782.
84. Bloom J, Hinrichs AL, Wang JC, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics. 2011;21(7):403-416.
85. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600-608.
86. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11.
87. Kaufmann A, Hitsman B, Goelz PM, et al. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Addict Behav. 2015;51:93-99.
88. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635-643.
89. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66(11):1253-1262.
90. Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396-398.
91. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98(4):288-295.
92. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobaccosmoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet. 2011;88(4):450-457.
93. Joubert BR, Håberg SE, Nilsen RM, et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect. 2012;120(10):1425-1431.
94. Philibert RA, Beach SR, Brody GH. Demethylation of the aryl hydrocarbon receptor repressor as a biomarker for nascent smokers. Epigenetics. 2012;7(11):1331-1338.
95. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet. 2012;21(13):3073-3082.
96. Zeilinger S, Kühnel B, Klopp N, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812.
97. Gao X, Jia M, Zhang Y, Breitling LP, Brenner H. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. Clin Epigenetics. 2015;7:113.
98. Shenker NS, Polidoro S, van Veldhoven K, et al. Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet. 2013;22(5):843-851.
99. Dogan MV, Shields B, Cutrona C, et al. The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics. 2014;15:151.
100. Elliott HR, Tillin T, McArdle WL, et al. Differences in smoking associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics. 2014;6(1):4.
101. Tsaprouni LG, Yang TP, Bell J, et al. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics. 2014;9(10):1382-1396.
102. Philibert RA, Beach SR, Lei MK, Brody GH. Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. Clin Epigenetics. 2013;5(1):19.
103. Markunas CA, Xu Z, Harlid S, et al. Identification of DNA methylation changes in newborns related to maternal smoking during pregnancy. Environ Health Perspect. 2014;122(10):1147-1153.
104. Richmond RC, Simpkin AJ, Woodward G, et al. Prenatal exposure to maternal smoking and offspring DNA methylation across the lifecourse: findings from the Avon Longitudinal Study of Parents and Children (ALSPAC). Hum Mol Genet. 2015;24(8):2201-2217.
105. Sun YV, Smith AK, Conneely KN, et al. Epigenomic association analysis identifies smoking-related DNA methylation sites in African Americans. Hum Genet. 2013;132(9):1027-1037.
106. Zhang Y, Yang R, Burwinkel B, et al. F2RL3 methylation in blood DNA is a strong predictor of mortality. Int J Epidemiol. 2014;43(4):1215-1225.
107. Reynolds LM, Wan M, Ding J, et al. DNA methylation of the aryl hydrocarbon receptor repressor associations with cigarette smoking and subclinical atherosclerosis. Circ Cardiovasc Genet. 2015;8(5):707-716.
108. Dietz PM, Homa D, England LJ, et al. Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States. Am J Epidemiol. 2011;173(3):355-359.
109. Connor Gorber S, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res. 2009;11(1):12-24.
110. Benowitz NL, Hukkanen J, Jacob P, III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009(192):29-60.
111. Sandberg A, Sköld CM, Grunewald J, Eklund A, Wheelock ÅM. Assessing recent smoking status by measuring exhaled carbon monoxide levels. PLoS One. 2011;6(12):e28864.
112. Jarvis MJ, Russell MA, Benowitz NL, Feyerabend C. Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health. 1988;78(6):696-698.
113. Wall MA, Johnson J, Jacob P, Benowitz NL. Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health. 1988;78(6):699-701.
114. Relton CL, Hartwig FP, Davey Smith G. From stem cells to the law courts: DNA methylation, the forensic epigenome and the possibility of a biosocial archive. Int J Epidemiol. 2015;44(4):1083-1093.
115. Shenker NS, Ueland PM, Polidoro S, et al. DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology. 2013;24(5):712-716.
116. Zhang Y, Yang R, Burwinkel B, Breitling LP, Brenner H. F2RL3 methylation as a biomarker of current and lifetime smoking exposures. Environ Health Perspect. 2014;122(2):131-137.
117. Teschendorff AE, Yang Z, Wong A, et al. Correlation of smoking-associated DNA methylation changes in buccal cells with DNA methylation changes in epithelial cancer. JAMA Oncol. 2015;1(4):476-485.
118. Beachy SH, Johnson SG, Olsen S, Berger AC, eds. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop Summary. Washington, DC: The National Academies Press, Institute of Medicine of the National Academies; 2014.
119. David SP, Bergen AW, Munafo M, et al. Genomic analysis to guide choice of treatment for smoking cessation. Cochrane Database of Systematic Reviews. 2015.
120. Hendershot T, Pan H, Haines J, et al. Using the PhenX Toolkit to Add Standard Measures to a Study. Curr Protoc Hum Genet. 2015;86:1.21.1-1.2117.